Proficiency testing of human leukocyte antigen-DR and human leukocyte antigen-DQ genetic risk assessment for type 1 diabetes using dried blood spots

Journal of Diabetes Science and Technology

Volumn 4, Issue 4, 2010, Pages 929-941

  Dantonio, Paul ^a   Meredith Molloy, Nancy ^a   Hagopian, William A ^b   She, Jin Xiong ^c   Akolkar, Beena ^d   Cordovado, Suzanne K ^a   Hendrix, Miyono ^a   Henderson, L Omar ^a   Hannon, W Harry ^a   Vogt, Robert F ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Newborn screening; Quality assurance; Quality control; The environmental determinants of diabetes in the young

Indexed keywords

HLA DQ ANTIGEN; HLA DR ANTIGEN;

ADULT; ARTICLE; AUTOSOME; BLOOD; CHEMISTRY; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE; PREDICTION AND FORECASTING; RISK ASSESSMENT; STANDARD;

ADULT; CHROMOSOMES, HUMAN, 1-3; DIABETES MELLITUS, TYPE 1; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; LEUKOCYTES; PREDICTIVE VALUE OF TESTS; REFERENCE STANDARDS; RISK ASSESSMENT;

EID: 78049493498     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400424     Document Type: Article

References (25)

1. Kiviniemi M, Hermann R, Nurmi J, Ziegler AG, Knip M, Simell O, Veijola R, Lövgren T, Ilonen J, TEDDY study group. A high-throughput population screening system for the estimation of genetic risk for type 1 diabetes: An application for the TEDDY (The Environmental Determinants of Diabetes in the Young) study. Diabetes Technol Ther. 2007;9(5):460-72.
2. Berger M, Stassen HH, Köhler K, Krane V, Mönks D, Wanner C, Hoffmann K, Hoffmann MM, Zimmer M, Bickeböller H, Lindner TH. Hidden population substructures in an apparently homogeneous population bias association studies. Eur J Hum Genet. 2006;14(2):236-44.
3. Hagopian WA, Lernmark A, Rewers MJ, Simell OG, She JX, Ziegler AG, Krischer JP, Akolkar B. TEDDY--The Environmental Determinants of Diabetes in the Young: an observational clinical trial. Ann NY Acad Sci. 2006;1079:320-6.
4. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann NY Acad Sci. 2008;1150:1-13.
5. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes. 2007;8(5):286-98.
6. Dantonio P, Meredith N, Earley M, Cordovado S, Callan WJ, Rollin D, Morris D, Vogt RF, Hannon WH. A screening system for detecting genetic risk markers of type 1 diabetes in dried blood spots. Diabetes Technol Ther. 2006;8(4):433-43.
7. Clinical and Laboratory Standards Institute (CLSI). Blood collection on filter paper for newborn screening programs; approved standard. Fifth ed. CLSI document LA4-A5. Wayne: Clinical and Laboratory Standards Institute; 2007.
8. Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M, McDuffie RS Jr, Hamman RF, Klingensmith G, Eisenbarth GS, Erlich HA. Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia. 1996;39(7):807-12.
9. Buzzetti R, Galgani A, Petrone A, Del Buono ML, Erlich HA, Bugawan TL, Lorini R, Meschi F, Multari G, Pozzilli P, Locatelli M, Bottazzo G, Di Mario U. Genetic prediction of type 1 diabetes in a population with low frequency of HLA risk genotypes and low incidence of the disease (the DIABFIN study). Diabetes Metab Res Rev. 2004:20(2);137-43.
10. Sjöroos M, Ilonen J, Reijonen H, Lövgren T. Time-resolved fluorometry based sandwich hybridisation assay for HLA-DQA1 typing. Dis Markers. 1998;14(1):9-19.
11. Wion E, Brantley M, Stevens J, Gallinger S, Peng H, Glass M, Hagopian W. Population-wide infant screening for HLA-based type 1 diabetes risk via dried blood spots from the public health infrastructure. Ann NY Acad Sci. 2003;1005:400-3.
12. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet. 2009;373(9680):2027-33.
13. Dabelea D. The accelerating epidemic of childhood diabetes. Lancet. 2009;373(9680):1999-2000.
14. Cardwell CR, Stene LC, Joner G, Cinek O, Svenesson, J, Goldacre MJ, Parslow RC, Pozzilli P, Brigis G, Stoyanov D, Urbonaite B, Sipetić S, Schober E, Ionescu-Tirgoviste C, Devoti G, de Beaufort CE, Buschard K, Patterson CC. Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia. 2008;51(5):726-35.
15. Lernmark B, Lynch K, Lernmark A. Cord blood islet autoantibodies are related to stress in the mother during pregnancy. Ann NY Acad Sci. 2006;1079:345-9.
16. Harris SS. Vitamin D in type 1 diabetes prevention. J Nutr. 2005;135(2):323-5.
17. Sanjeevi CB, Schatz DA, Atkinson MA. Immunology of diabetes V: from bench to bedside. New York Academy of Science: 2008.
18. Fung EY, Smyth DJ, Howson JM, Cooper JD, Walker NM, Stevens H, Wicker LS, Todd JA. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun. 2009;10(2):188-91.
19. Concannon P, Chen WM, Julier C, Morahan G, Akolkar B, Erlich HA, Hilner JE, Nerup J, Nierras C, Pociot F, Todd JA, Rich SS, Type 1 Diabetes Genetics Consortium. Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the Type 1 Diabetes Genetics Consortium. Diabetes. 2009;58(4):1018-22.
20. Yoshida K, Corper AL, Herro R, Jabri B, Wilson IA, Teyton L. The diabetogenic mouse MHC class II molecule I-Ag7 is endowed with a switch which modulates TCR affinity. J Clin Invest. 2010:120(5):1578-90.
21. Ilonen J, Sjöroos M, Knip M, Veijola R, Simell O, Akerblom HK, Paschou P, Bozas E, Havarani B, Malamitsi-Puchner A, Thymelli J, Vazeou A, Bartsocas CS. Estimation of genetic risk for type 1 diabetes. Am J Med Genet. 2002;115(1):30-6.
22. .Rewers A, Klingensmith G, Davis C, Petitti DB, Pihoker C, Rodriguez B, Schwartz ID, Imperatore G, Williams D, Dolan LM, Dabelea D. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth study. Pediatrics. 2008;121(5):e1258-66.
23. Barker JM, Goehrig SH, Barriga K, Hoffman M, Slover R, Eisenbarth GS, Norris JM, Klingensmith GJ, Rewers M, DAISY Study. Clinical characteristics of children with diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004;27(6):1399-404.
24. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Immune Tolerance Network ITN007AI Study Group. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009;132(2):166-73.
25. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008;359(18):1909-20.